BioLargo, Inc. President
and CEO Dennis Calvert was recently interviewed by OCTANe OC, a leading innovation cluster
based in Orange County, on BioLargo’s technology, its vision, and its strategy
to achieve future growth. The interview was part of a comprehensive assessment
for OCTANe’s High Tech Innovation Award
(HTIA), a prestigious industry award that recognizes outstanding technology innovators
in Orange County. 
We’re excited to announce that BioLargo has been chosen as a finalist
for this year’s (2017) OCTANe HTIA award. It’s no surprise that the company was
not only nominated, but also made a finalist this year – 2017 has been a year
of tremendous progress for BioLargo, both technologically and commercially. Its
subsidiary, Odor-No-More, signed
multiple national purchasing agreements with some of the largest solid
waste management companies in North America this year for its industrial odor
control product CupriDyne Clean, signalling
meaningful commercial traction in this large and underserved market. Clyra Medical Technologies,
another BioLargo subsidiary, completed development of its iodine-based advanced
wound care products and is preparing submission for its product for FDA 510(K)
application in the near future. And importantly, BioLargo’s Advanced Oxidation
System (AOS) made significant strides toward commercialization, with more than
35 awarded grants, 3 commercial validation trials underway and potential
engineering and scale-up partners under evaluation. |
| BioLargo AOS being tested in the lab |
Dennis P. Calvert, President & CEO of BioLargo
commented, “OCTANEe is building a dynamic ecosystem in Orange County to support
technology innovation like ours. We are
proud to be chosen by such a prestigious group of companies.
Other finalists for this year’s HTIA award include
well-known computer technology companies such as HyperX and D-LINK, along with
innovative biotechnology, medical, and software companies. Clearly, 2017
yielded an impressive list of finalists. For a full list of OCTANe HTIA
finalists, go here.
No comments:
Post a Comment